Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H10NO3.Na |
| Molecular Weight | 275.2346 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)C1=CC2=C(O1)C=CC(CC3=CN=CC=C3)=C2
InChI
InChIKey=XBTIPIZROJAKOJ-UHFFFAOYSA-M
InChI=1S/C15H11NO3.Na/c17-15(18)14-8-12-7-10(3-4-13(12)19-14)6-11-2-1-5-16-9-11;/h1-5,7-9H,6H2,(H,17,18);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H10NO3 |
| Molecular Weight | 252.2448 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P24557|||Q8IUN1|||Q9HD82 Gene ID: 6916.0 Gene Symbol: TBXAS1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
The absorption and disposition of the parent drug in normal male volunteers have been studied after single- and multiple-dose oral administration. The results from the single-dose study indicate that furegrelate is rapidly absorbed, with a Tmax of 1.0-1.7 hr, has an apparent terminal disposition rate constant of 0.12-0.17 hr-1, and is eliminated primarily by the kidney, with 62-78% of the dose excreted as parent drug
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: U-63557A (furegrelate) could potentiate the effects of Eicosapentaenoic acid (EPA) on postischemic cerebral blood flow (CBF) in ischemic gerbils. Ischemia was produced by bilateral carotid artery occlusion for 15 minutes followed by reperfusion for 2 hours
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:56:53 UTC 2023
by
admin
on
Sat Dec 16 06:56:53 UTC 2023
|
| Record UNII |
4F11B27M90
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
85666-17-7
Created by
admin on Sat Dec 16 06:56:53 UTC 2023 , Edited by admin on Sat Dec 16 06:56:53 UTC 2023
|
PRIMARY | |||
|
23663954
Created by
admin on Sat Dec 16 06:56:53 UTC 2023 , Edited by admin on Sat Dec 16 06:56:53 UTC 2023
|
PRIMARY | |||
|
4F11B27M90
Created by
admin on Sat Dec 16 06:56:53 UTC 2023 , Edited by admin on Sat Dec 16 06:56:53 UTC 2023
|
PRIMARY | |||
|
DTXSID8045226
Created by
admin on Sat Dec 16 06:56:53 UTC 2023 , Edited by admin on Sat Dec 16 06:56:53 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
